CANSINO BIOLOGICS INC. (CanSinoBIO) is China`s dynamic bio-tech leader blazing new paths in R&D,manufacturing and commercialisation of vaccine products for human use. Founded in the Tianjin Economic and Technological Development Area (TEDA)in 2009, Founders of CanSinoBIO formed a superb team of scientists and managers who had previously held senior management and technical positions at many of the world leading pharmaceutical companies. To date, the management team has boasted a proven track record of success in new drug discovery, development and commercialisation.
InnoCare is a clinical stage biopharmaceutical company committed to discovering, developing and commercializing best-in-class and/or first-in-class drugs for the treatment of cancer and autoimmune diseases. Led by a world-class management team of seasoned industry executives, we have built a fully integrated biopharmaceutical platform with strong in-house R&D capabilities. Our vision is to become a global biopharmaceutical leader that develops anddelivers innovative therapies for patients worldwide.
Investment in an interventional medical device company focused on cardiovascular diseases. The company currently has two products in the pipeline: 1) coronary drug coated balloons (DCB); and 2) left atrial appendage (LAA) occluder. The company plans to expand its product portfolio via R&D and acquisition, aiming to become a leading interventional medical device company in China.
Imperative Care is singularly dedicated to finding meaningful answers to unsolved problems in stroke. Founded by experienced healthcare leaders and clinical advisors, Imperative Care understands the vast and urgent needs in stroke. Our focus is on medical technology designed to expedite and improve the effectiveness of treatment, giving patients a chance for optimal recovery.
Investment in a medical device company primarily focused on neurovascular intervention in China. With the purpose of building a holistic treatment platform for stroke patients, the company has a broad pipeline portfolio covering neurovascular access, ischemic stroke and hemorrhagic stroke.